German biopharmaceutical company Boehringer Ingelheim's China arm has inked a strategic cooperation agreement with Chinese high-tech company ChromX Health, to jointly push forward research on interstitial lung diseases and search for innovative early diagnosis and intervention solutions.
Interstitial lung diseases, or ILD, are a large group of disorders that can cause progressive scarring of lung tissue if not treated timely and effectively, resulting in difficulty to breathe and even death.
